Key facts
- Notable investors include Draper Associates, Boost VC.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Muse.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Muse.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Muse.Bio
Operator of a stem cells collector and a stem cells biobank platform intended to make safer and simpler access of cells for patients and researchers. The company provides a platform where they collect, store and transform stem cells from menstrual blood, enabling patients easy access to stem cells and lower procurement cost for researchers to make medicines.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 4
- Website
- mycells.bio/
- Ownership
- Privately Held (backing)
Muse.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Muse.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Muse.Bio in its N-PORT filings yet. We sweep new filings monthly.